GSK drops OTC eczema itch drug
GlaxoSmithKline has discontinued the development of candidate eczematreatment ADL 2-1294, which was intended as an over-the-counter product for the alleviation of itching associated with the skin condition. GSK said that the decision was taken because the drug had not performed significantly better than placebo in a Phase II evaluation, despite encouraging signs of activity in preclinical and early clinical trials.
ADL 2-1294 (which contains the active ingredient loperamide, currently used as an antidiarrheal agent) was licensed to SmithKline Beecham by US group Adolor in 1999, prior to SB's merger with Glaxo Wellcome.
Adolor noted that Santen Pharmaceutical of Japan will continue to develop ADL 2-1294 for the treatment of ophthalmic pain. The two firms entered into a separate development and licensing agreement for the topical uses of ADL 2-1294 for this indication last April.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze